Researchers want to use radio frequency identification (RFID) chips for keeping track of organoids, samples of human tissue that mimic pieces of organs and are grown from stem cells. The organoids the researchers embedded with RFID chips functioned normally and withstood extreme conditions, suggesting that they could be a useful way to organize and identify the large quantities of organoids needed in experimental situations.

Radio frequency identification (RFID) chips are used today for everything from paying for public transit to tracking livestock to stopping shoplifters. But now, researchers in the U.S. and Japan want to use them for something else: keeping track of organoids, samples of human tissue that mimic pieces of organs and are grown from stem cells.

The organoids the researchers embedded with RFID chips functioned normally and withstood extreme conditions, suggesting that they could be a useful way to organize and identify the large quantities of organoids that are often needed in experimental situations. The work appears in the journal iScience.

"This kind of multidisciplinary approach potentially offers a disruptive way forward: the idea is to combine organoids with digital technologies to advance drug testing and transplantation," says senior author Takanori Takebe.

Grown from human induced pluripotent stem cells, they divide, differentiate, and self-assemble according to the growth programs of their corresponding organs. And particularly in medicine, they can illustrate the effects of certain drugs on our organs in ways that more traditional cell cultures cannot.

The idea of embedding microchips into human organoids seemed like a natural fit to Takebe, who has worked extensively with RFID chips in health contexts. The chips could be used to sense, record, and track interesting changes live in large quantities of organoids at once — and because cells self-assembled into 3D structures during the growth process of an organoid, he thought it might be possible for the microchips to be naturally integrated into the organoids as they were growing.

"Introducing the chips by forceful methods like injection is extremely toxic to organoids, so we leveraged the organoid's natural self-cavitation power to integrate the microchips so that we could prevent tissue damage and destruction," he says.

To test this procedure, he and his team grew hybrid liver organoids containing cheap, commercially available RFID chips the size of grains of sand. They found that 95% of their 96 test organoids successfully incorporated the chip. The organoids were undamaged by the procedure: they were shaped normally, secreted by normal liver proteins, and transported bile as expected. "There were almost no differences, surprisingly," says Takebe.

The RFID chips, which are known for their durability, also functioned as expected. Hybrid organoids grown from stem cells of donors with the fatty liver disease could be identified by RFID in a pool of organoids from a variety of donors.

Takebe acknowledges that there are still limitations with this approach. More work needs to be done to scale up the production of these hybrid organoids, and he and his team are currently working to develop a system that could scan the radio frequency and fluorescence of an organoid at the same time. He also hopes that other kinds of microchips could be integrated into organoids in the future and that RFID chips with sensing technologies could be used to record real-time data about the organoids.